Author:
Lucioni C.,Mazzi S.,Pari B.,Bonello M.,Mazzanti B.,Fresca G.,Fagotti M.,Goretti M. B.,Rossi G.,Giuliani G. E.,Patregnani L.,Bogino C.,D’Orsi M.,Tinella M.,Zuccotti G. F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy
Reference21 articles.
1. National Center for Chronic Disease Prevention and Health Promotion. Preventing heart disease and stroke (online: www.cdc.gov/nccdphp/bb_heartdisease/index.htm )
2. Task Force for Compliance. Non compliance with medication regimens: an economic tragedy: emerging issues in pharmaceutical cost containing. Washington, DC: National Pharmaceutical Council, 1994: 1–32
3. Mc Ghan WF, Peterson AM. Pharmacoeconomic impact of non-compliance. Bridgewater, NJ: US Pharmacist Impact, 2001: 3–13
4. Stamler J, Wentwoeth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on primary screens of the Multiple Risk Factor Intervention Trial. Am J Med 1986; 80: 33–9
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献